StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
2651.HK$11.77-6.59%
Fair $11.77+0.0%

2651.HK

Wuhan Dazhong Dental Medical Co., Ltd.

Healthcare / Medical Care FacilitiesHKSE

$11.77

-0.83 (-6.59%)

Fairly Valued+0.0%Fair Value $11.77Fund rank 38/100 · Data gapFallback financials|
SA 51/C
F-Score: 5/9
Declining Revenue

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 24% · confianza 25%

FCF escenarios

weak_data · normalized FCF $80.1M · quality 83.7/100

Data gap 38/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 83/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

51/100

C

Piotroski

5/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. Revenue has declined for 2 consecutive years
Thesis & Journal · 2651.HKLocal privado en este navegador · Wuhan Dazhong Dental Medical Co., Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$581M

P/E

15.9x

↓

EV/EBITDA

3.0x

↓

ROE

8.8%

↑

Gross Margin

37.7%

↓

Debt/Equity

0.23

↑
52-Week Range$12
$8$28

TradingView lightweight chart

2651.HK price, volumen y niveles de valoración

Último $11.77Periodo -43.1%
Fair value: $11.77

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-3.2%

FCF CAGR

-8.6%

FCF margin

21.6%

FCF / Net income

2.84x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $371.6M · net income $28.2M · FCF $80.1M

2022-FY → 2025-FY

Gross margin

37.7%+1.4% pts

Operating margin

17.7%+1.2% pts

Net margin

7.6%-3.0% pts

FCF margin

21.6%-4.1% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$371.6M$371.6M$407.1M$441.8M$409.4M
Net Income$28.2M$28.2M$41.9M$50.1M$43.3M
EBITDA$114.0M$114.0M$132.8M$145.3M$133.5M
EPS0.640.640.741.010.88
Gross Margin37.7%37.7%37.4%38.1%36.3%
Operating Margin17.7%17.7%18.8%19.2%16.5%
Net Margin7.6%7.6%10.3%11.3%10.6%
Balance Sheet
Debt/Equity0.230.230.980.770.96
Current Ratio3.353.35———
Cash Flow
Free Cash Flow$80.1M$80.1M$77.2M$130.5M$105.1M
Returns
ROE8.8%8.8%36.2%38.1%37.3%
Valuation
P/E15.9115.91———
EV/EBITDA2.972.97———
P/B1.611.61———
Growth & Yield
Revenue Growth-8.7%-8.7%-7.9%7.9%—
EPS Growth-13.5%-13.5%-27.0%15.5%—
Dividend Yield6.1%6.1%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

17.7%

exigente

EPS terminal req.

$1.04

Spread vs growth

-31.2%

5Y implied EPS CAGR

14.6%

razonable

EPS terminal req.

$1.26

Spread vs growth

-28.1%

10Y implied EPS CAGR

12.3%

razonable

EPS terminal req.

$2.04

Spread vs growth

-25.8%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · available periodreconcilia total -37.1%

Total return

-37.1%

Start / end P/E

28.0x → 18.4x

EPS bridge

0.74 → 0.64

Residual

+4.6%

EPS growth-13.5%
Multiple rerating-34.3%
Dividend+6.1%
Residual / FX / buybacks / cross-term+4.6%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.